Literature DB >> 1650741

Cell associated urokinase activity and colonic epithelial cells in health and disease.

P R Gibson1, E van de Pol, W F Doe.   

Abstract

It is not known if urokinase-type plasminogen activator (uPA) is associated with normal colonic epithelial cells. The aims of this study were to determine if normal colonic epithelial cells have uPA activity and whether this is concentrated at the cell membrane. In addition, the contribution of colonic epithelial cell associated uPA activity to disease related pertubations of mucosal uPA activity were examined. A highly enriched population of colonic epithelial cells was isolated from resected colon or biopsy specimens by an enzymatic technique. uPA activity was measured in cell homogenates by a specific and sensitive colorimetric method and expressed relative to cellular DNA. In two experiments subcellular fractionation of colonic epithelial cells was performed by nitrogen cavitation followed by ultracentrifugation over a linear sucrose gradient. The fractions collected were analysed for uPA and organelle-specific enzyme activities. Normal colonic epithelial cells have cell associated uPA activity (mean (SEM) 5.6 (1.1) IU/mg, n = 18). This colocalised with fractions enriched for leucine-beta-naphthylamidase and 5'-nucleotidase, markers of plasma membrane. uPA activities in epithelial cells from cancerous colons (9.8 (3.1) n = 7) or from mucosa affected by inflammatory bowel disease (3.8 (0.7) n = 15) were not significantly different from normal (paired t test), while that in epithelial cells from greatly inflamed mucosa was similar to that from autologous normal or mildly inflamed areas (4.4 (1.2) v 5.9 (3.6), n = 9). Thus normal colonic epithelial cells have cell associated uPA activity which is concentrated on the plasma membranes, suggesting the presence of uPA receptors. Increased mucosal levels of uPA previously reported in patients with inflammatory bowel disease are not due to increased colonic epithelial cell associated uPA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650741      PMCID: PMC1378807          DOI: 10.1136/gut.32.2.191

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Isolation of colonic crypts that maintain structural and metabolic viability in vitro.

Authors:  P R Gibson; E van de Pol; L E Maxwell; A Gabriel; W F Doe
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

2.  Effect of urokinase on the proliferation of primary cultures of human prostatic cells.

Authors:  J C Kirchheimer; J Wojta; G Hienert; G Christ; M E Heger; H Pflüger; B R Binder
Journal:  Thromb Res       Date:  1987-11-01       Impact factor: 3.944

Review 3.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

4.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

5.  Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.

Authors:  D Boyd; G Florent; P Kim; M Brattain
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

6.  Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?

Authors:  J S Gelister; M R Lewin; H E Driver; F Savage; M Mahmoud; P J Gaffney; P B Boulos
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

7.  Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.

Authors:  P S Sim; R W Stephens; D R Fayle; W F Doe
Journal:  Int J Cancer       Date:  1988-10-15       Impact factor: 7.396

8.  Plasminogen activators in the intestine of patients with inflammatory bowel disease.

Authors:  P A de Bruin; G Crama-Bohbouth; H W Verspaget; J H Verheijen; G Dooijewaard; I T Weterman; C B Lamers
Journal:  Thromb Haemost       Date:  1988-10-31       Impact factor: 5.249

9.  Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.

Authors:  S Kohga; S R Harvey; R M Weaver; G Markus
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

10.  Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration.

Authors:  L Ossowski; J P Quigley; G M Kellerman; E Reich
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

View more
  6 in total

Review 1.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro.

Authors:  P Gibson; O Rosella; G Rosella; G Young
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

3.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

4.  Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.

Authors:  P Protiva; I Sordat; P Chaubert; E Saraga; C Trân-Thang; B Sordat; A L Blum; G Dorta
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

Review 5.  Development and Testing of Thrombolytics in Stroke.

Authors:  Dmitri Nikitin; Seungbum Choi; Jan Mican; Martin Toul; Wi-Sun Ryu; Jiri Damborsky; Robert Mikulik; Dong-Eog Kim
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

6.  Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.

Authors:  Elisavet Karamanavi; Katerina Angelopoulou; Sophia Lavrentiadou; Anastasia Tsingotjidou; Zaphiris Abas; Ioannis Taitzoglou; Ioannis Vlemmas; Suzan E Erdman; Theofilos Poutahidis
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.